Delivery Order SPE2DB20D1100-SPE2DB24FB9X0

Award Date 5/28/24
Potential Completion Date 5/29/24
Potential Value $8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for the supply of Pulmozyme (dornase alfa) medication in 2.5 ml ampules. The contract has a ceiling value of $2,546.49 and is a Delivery Order with a Firm Fixed Price pricing type. The ultimate completion date is May 23, 2024. Amerisourcebergen holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml. The contract is a Delivery Order with a Firm Fixed Price of $25,335.45 and a period of performance through November 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
The U.S. Defense Logistics Agency (DLA) has awarded a delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Pulmozyme 1 mg/mL ampul 2.5 mL. The $2,410.99 firm fixed-price contract has a completion date of March 22, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA for a wide range of pharmaceutical products and medical supplies to support the Department of Defense worldwide. This...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a prescription medication. The award, valued at $2,410.99, is a firm-fixed-price delivery order with a completion date of June 13, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. The $30,161.60 firm fixed-price contract has a completion date of May 25, 2023 and is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a $27,880.43 firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has an ultimate completion date of September 20, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml. The contract has a firm fixed price of $4,717.94 and a completion date of December 4, 2024. It is designated as a delivery order contract type. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $91,225.17 Firm Fixed Price delivery order is for the supply of Pulmozyme 1 mg/ml ampul 2.5 ml, a medication used in the treatment of cystic fibrosis. The contract has an ultimate completion date of March 22, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for the delivery of Pulmozyme 1 mg/ml ampul 2.5 ml to the Defense Logistics Agency (DLA). The $4,769.60 firm fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
This federal contract award, valued at $68,193.74, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp for the supply of Pulmozyme 1 mg/ml ampules (2.5 ml). The contract has a firm fixed price and an ultimate completion date of August 14, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this delivery order under its Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FB9X0
    Delivery Order

This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Pulmozyme 1 mg/mL ampules in 2.5 mL quantities. The contract is a Delivery Order with a Firm Fixed Price type, valued at $8,017.10, and has an ultimate completion date of May 29, 2024.

Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This contract award did not have a set-aside designation.

Generated 8/27/24, 9:21 AM